The long-term objective of this project is to develop new methods for marrow transplantation using alternative donors for patients with hematologic malignancies who lack an HLA identical sibling.
Specific aims are: 1) to decrease morbidity and non-relapse mortality in transplants from unrelated donors. Human recombinant GM-CSF administered from day 0 to day +27 will be evaluated in a placebo-controlled, randomized, double-blind, phase III trial for the effect on engraftment, infection and regimen related toxicity. 2) to compare the outcome of transplants from unrelated donors who are partially HLA mismatched to those who are phenotypically HLA matched. Donors who differ by one HLA class I locus if the mismatched antigens fall within a crossreactive group, or differ by an HLA-DRB1 locus if the mismatched alleles fall within a single serologically defined specificity will be used for patients below 36 years of age. The rates of acute GVHD, transplant-related mortality and survival will be compared for patients with same age, disease, diagnosis and stage, and GVHD prophylaxis but different degree of HLA matching and 3) to decrease graft rejection and GVHD in recipients of HLA haplomismatched family member grafts. T-cell receptor/CD3 complex-specific antibody BC3 administered for 14 days beginning just before the marrow infusion will be evaluated in a phase I/II study to facilitate engraftment in patients with a positive anti-donor lymphocyte crossmatch, a group with the highest risk of graft rejection. 4) develop and assess functional assays that measure donor immune responses to the recipient's alloantigens, and determine if these assays will be useful for predicting GVHD and facilitating donor selection.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA018029-17
Application #
3793581
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
17
Fiscal Year
1992
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
075524595
City
Seattle
State
WA
Country
United States
Zip Code
98109
Deegan, Anthony J; Talebi-Liasi, Faezeh; Song, Shaozhen et al. (2018) Optical coherence tomography angiography of normal skin and inflammatory dermatologic conditions. Lasers Surg Med 50:183-193
Leger, Kasey J; Baker, K Scott; Cushing-Haugen, Kara L et al. (2018) Lifestyle factors and subsequent ischemic heart disease risk after hematopoietic cell transplantation. Cancer 124:1507-1515
Schmitt, Michael W; Pritchard, Justin R; Leighow, Scott M et al. (2018) Single-Molecule Sequencing Reveals Patterns of Preexisting Drug Resistance That Suggest Treatment Strategies in Philadelphia-Positive Leukemias. Clin Cancer Res 24:5321-5334
Shaw, Bronwen E; Syrjala, Karen L; Onstad, Lynn E et al. (2018) PROMIS measures can be used to assess symptoms and function in long-term hematopoietic cell transplantation survivors. Cancer 124:841-849
Jamani, Kareem; Onstad, Lynn E; Bar, Merav et al. (2018) Quality of Life of Caregivers of Hematopoietic Cell Transplant Recipients. Biol Blood Marrow Transplant 24:2271-2276
Ogimi, Chikara; Xie, Hu; Leisenring, Wendy M et al. (2018) Initial High Viral Load Is Associated with Prolonged Shedding of Human Rhinovirus in Allogeneic Hematopoietic Cell Transplant Recipients. Biol Blood Marrow Transplant 24:2160-2163
Salter, Alexander I; Pont, Margot J; Riddell, Stanley R (2018) Chimeric antigen receptor-modified T cells: CD19 and the road beyond. Blood 131:2621-2629
Lee, Stephanie J; Nguyen, Tam D; Onstad, Lynn et al. (2018) Success of Immunosuppressive Treatments in Patients with Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant 24:555-562
Bar, Merav; Flowers, Mary E D; Storer, Barry E et al. (2018) Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter Trial. Biol Blood Marrow Transplant 24:308-313
Armenian, Saro H; Yang, Dongyun; Teh, Jennifer Berano et al. (2018) Prediction of cardiovascular disease among hematopoietic cell transplantation survivors. Blood Adv 2:1756-1764

Showing the most recent 10 out of 1845 publications